Clinical Trial

The Impact of Pharmaceutical Care on the Infection Control Measures Among Hemodialytic Patients

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 13, 2025 (before its estimated May 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
The study aims to assess the effectiveness of pharmaceutical care in reducing infection rates among hemodialysis patients with central venous (CV) lines. It will evaluate the role of clinical pharmacists in optimizing infection management and antimicrobial use. Additionally, the study will examine the impact of pharmacist-led education on patient adherence to infection prevention and medication regimens. The role of pharmacists in reducing catheter-related bloodstream infections (CRBSIs) and other dialysis-related infections will also be investigated. Finally, the study will evaluate patient satisfaction and quality of life improvements resulting from pharmaceutical interventions in infection management.
Trial Details
NCT Number NCT06968754
Lead Sponsor University of Sulaimani
Conditions Infection, Hemodialysis Patients
Enrollment 90 participants
Start Date 2024-11-01
Primary Completion 2025-05-15 (estimated)
Study Completion 2025-05-15 (estimated)
Updated on ClinicalTrials.gov 2025-05-13